Advertisement
Advertisement
ZVRA
Zevra Therapeutics, Inc. Common Stock
11.13
USDSponsored
+0.13
+1.18%
May 08, 16:00 UTC -4
Closed
Pre-Market
11.20
+0.06
+0.58%
ZVRA Earnings Reports
Positive Surprise Ratio
ZVRA beat 21 of 42 last estimates.
50%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$34.88M
/$0.10
Implied change from Q1 26 (Revenue/ EPS)
-3.69%
/-44.44%
Implied change from Q2 25 (Revenue/ EPS)
+34.78%
/-91.74%
Zevra Therapeutics, Inc. Common Stock earnings per share and revenue
On May 06, 2026, ZVRA reported earnings of 0.18 USD per share (EPS) for Q1 26, beating the estimate of 0.08 USD, resulting in a 118.45% surprise. Revenue reached 36.22 million, compared to an expected 32.60 million, with a 11.11% difference. The market reacted with a -2.22% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of 0.10 USD, with revenue projected to reach 34.88 million USD, implying an decrease of -44.44% EPS, and decrease of -3.69% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Zevra Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Zevra Therapeutics, Inc. Common Stock reported EPS of $0.18, beating estimates by 118.45%, and revenue of $36.22M, 11.11% above expectations.
How did the market react to Zevra Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -2.22%, changed from $11.25 before the earnings release to $11.00 the day after.
When is Zevra Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Zevra Therapeutics, Inc. Common Stock's next earnings report?
Based on 7
analysts, Zevra Therapeutics, Inc. Common Stock is expected to report EPS of $0.10 and revenue of $34.88M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement